Overall Survival Outcomes and CNS Activity of Crizotinib in Patients With ROS1-Rearranged NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial
ESMO Open 2024 Feb 01;9(2)102237, S Michels, B Massutí, I Vasyliv, J Stratmann, J Frank, A Adams, E Felip, C Grohé, D Rodriguez-Abreu, H Bischoff, E Carcereny I Costa, J Corral, E Pereira, J Fassunke, RN Fischer, A Insa, S Koleczko, L Nogova, M Reck, T Reutter, R Riedel, D Schaufler, M Scheffler, M Weisthoff, M Provencio, S Merkelbach-Bruse, M Hellmich, M Sebastian, R Büttner, T Persigehl, R Rosell, J WolfFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.